Peptide regulation and evidence, from primary sources
We track FDA decisions on peptides, 503A and 503B compounding lists, warning letters, Pharmacy Compounding Advisory Committee meetings, and registered clinical trials. Every claim links to the original document. We never publish dosing information or vendor links.
Latest
Compounded vs. FDA-Approved Peptides: What the Difference Means
What FDA says about compounded drugs versus FDA-approved drugs, 503A pharmacies vs 503B outsourcing facilities, and buying compounded drugs online.
FDA's 503A Bulks List and Interim Categories Explained, and Where BPC-157 Stands in 2026
A source-linked explainer on how FDA's 503A bulks list and interim categories 1-3 work, and FDA's July 2026 PCAC proposal on BPC-157.